Sign Out
There is limited clinical trial experience with doses higher than the approved intravenous dose of ocrelizumab. The highest dose tested to date in MS patients is 2000 mg, administered as two 1000 mg intravenous infusions separated by 2 weeks (Phase II dose finding study in RRMS). The adverse reactions were consistent with the safety profile in the pivotal clinical studies.
There is no specific antidote in the event of an overdose; interrupt the infusion immediately and observe the patient for IRRs (see Precautions).
